Clinical trials Below are current clinical trials.553 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Rochester, Minn., Jacksonville, Fla. The primary objective of this study is to determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) in patients with higher sodium-dependent phosphate transport protein 2b (NaPi2b) expressing platinum-resistant high-grade serous ovarian cancer (HGSOC), including cancers of ovarian, fallopian tube or primary peritoneal origin) Note: Mayo Clinic is only participating in the Phase 2 - Cohort 3 (UPLIFT) portion of the study. Mayo Clinic will not be participating in the QTC sub-study. Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Jacksonville, Fla., Rochester, Minn. The purpose of this study is to observe the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) Rochester, Minn. The primary objective of the United States Food and Drug Administration (FDA) for this study is to demonstrate non-inferiority in subjects who received an allogeneic BMT for subjects randomized to Rezafungin for Injection compared to subjects randomized to the standard antimicrobial regimen (SAR) for fungal-free survival at Day 90 (±7 days). The primary objective of the European Medicines Agency (EMA) for this study is to demonstrate superiority in subjects who received an allogeneic BMT randomized to Rezafungin for Injection compared to subjects randomized to the SAR for fungal-free survival at Day 90 (±7 days). Patient Outcomes after Hepatic Artery Infusion Pump Placement Rochester, Minn. The purpose of this study is to evaluate the short-term outcomes and the quality of life (QOL) after cholecystectomy and hepatic artery infusion pump placement for localized unresectable colorectal liver metastases (CRLM). Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Mankato, Minn., La Crosse, Wis., Eau Claire, Wis., Albert Lea, Minn. The purpose of this study is to collect blood and tissue samples from patients with and without cancer to evaluate laboratory tests for early cancer detection which may help researchers develop tests for the early detection of cancers. Study of RP-6306 With FOLFIRI in Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib and rituximab alone. Epidemiology of Chronic Lymphocytic Leukemia Rochester, Minn. The overall goals of this study are to evaluate similarities and differences of the known genetic and non-genetic epidemiological factors associated with chronic lymphocytic leukemia (CLL) risk across African Americans, Hispanics, and Caucasian populations. SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy Jacksonville, Fla. The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS). Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy Rochester, Minn. The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review. To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. Pagination Clinical studies PrevPrevious Page Go to page 1010 Go to page 1111 Go to page 1212 Go to page 1313 Go to page 1414 NextNext Page Request an appointment Expertise & rankingsResearch May 09, 2023 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation for 2023-2024 by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 departments-centers Oncology (Medical)